JP2015511957A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511957A5
JP2015511957A5 JP2014560367A JP2014560367A JP2015511957A5 JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5 JP 2014560367 A JP2014560367 A JP 2014560367A JP 2014560367 A JP2014560367 A JP 2014560367A JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5
Authority
JP
Japan
Prior art keywords
salt
ethoxy
arginine
phosphonoethoxy
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511957A (ja
JP6325986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054548 external-priority patent/WO2013131985A1/en
Publication of JP2015511957A publication Critical patent/JP2015511957A/ja
Publication of JP2015511957A5 publication Critical patent/JP2015511957A5/ja
Application granted granted Critical
Publication of JP6325986B2 publication Critical patent/JP6325986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560367A 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩 Active JP6325986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
US61/608,011 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (3)

Publication Number Publication Date
JP2015511957A JP2015511957A (ja) 2015-04-23
JP2015511957A5 true JP2015511957A5 (https=) 2016-04-28
JP6325986B2 JP6325986B2 (ja) 2018-05-16

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560367A Active JP6325986B2 (ja) 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩

Country Status (18)

Country Link
US (1) US9320748B2 (https=)
EP (1) EP2822947B1 (https=)
JP (1) JP6325986B2 (https=)
CN (1) CN104203946B (https=)
AU (1) AU2013229466A1 (https=)
CA (1) CA2865759C (https=)
CY (1) CY1118091T1 (https=)
DK (1) DK2822947T3 (https=)
ES (1) ES2597755T3 (https=)
HR (1) HRP20161354T1 (https=)
HU (1) HUE030175T2 (https=)
LT (1) LT2822947T (https=)
MX (1) MX346678B (https=)
PL (1) PL2822947T3 (https=)
PT (1) PT2822947T (https=)
RU (1) RU2014140336A (https=)
SI (1) SI2822947T1 (https=)
WO (1) WO2013131985A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN106103469B (zh) 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502366A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン エセ.ピー.アー. Chlamydiapneumoniaeに対する免疫化
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
RU2007146137A (ru) 2005-05-12 2009-06-27 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Иммуногенные композиции на основе chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2633142A1 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, S.R.L. Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
JP5867952B2 (ja) * 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты

Similar Documents

Publication Publication Date Title
JP2015511957A5 (https=)
JP2013534248A5 (https=)
CN112469713A (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
RU2014140336A (ru) Иммунологически полезные соли аргинина
JP2013515742A5 (https=)
JP2014525429A5 (https=)
JP2018531941A5 (https=)
JP2014051497A5 (https=)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2015017821A3 (en) Therapeutically active compounds and their methods of use
JP2016532722A5 (https=)
JP2014500861A5 (https=)
JP2014507446A5 (https=)
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP2012513416A5 (https=)
JP2016531894A5 (https=)
JP2019516739A5 (https=)
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
JP2016516074A5 (https=)
JP2014218522A5 (https=)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
JP2015522037A5 (https=)
JP2015516419A5 (https=)